{"filings":[{"id":77962,"accession_number":"0001104659-26-060726","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2026-05-14T12:06:12+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx Q1 net loss $46.3M; reacquires bota-vec from J&J; raises $100M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to ordinary shareholders was $46.3M ($0.57 per share) for Q1 2026, vs $40.0M ($0.51) in Q1 2025.","Cash and cash equivalents were $71.5M at March 31, 2026; subsequent $100M equity offering and $25M upfront payment to J&J for bota-vec.","Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia; positive 3-year data from Phase 1 AQUAx study.","Appointed Penny Fleck as Chief Development Officer; Stuart Naylor as Chief Scientific Officer, Ophthalmology.","Reacquired full rights to bota-vec for XLRP from J&J with $25M upfront plus milestones and mid-teens royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95078,"accession_number":"0001104659-26-048196","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MeiraGTx closes initial $200M Hologen collaboration; Hologen to own 70% of neuro JV","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Completed initial closing of strategic collaboration with Hologen on April 20, 2026; Hologen provided $200M upfront cash payment.","Hologen to fund remaining portion of upfront via post-completion share purchases, ultimately owning 70% of HNAI and minority stake in MeiraGTx Manufacturing.","Collaboration covers AAV-GAD for Parkinson's disease, AAV-BDNF for genetic obesity disorders, and proprietary CNS delivery device.","MeiraGTx Neuro UK retains 30% of HNAI; Hologen gets exclusive option to buy up to 40% of MeiraGTx Manufacturing shares within 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95077,"accession_number":"0001104659-26-044462","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MeiraGTx prices $100M public offering of 11.1M shares at $9.00 each; net proceeds ~$93.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["11,111,111 ordinary shares at $9.00/sh; net proceeds ~$93.3M after underwriting discounts and expenses.","Closing expected April 17, 2026; proceeds for general corporate purposes, working capital, capital expenditures.","Cash plus net proceeds expected to fund operating expenses and capital needs into H2 2028, including potential launches of bota-vec and AAV-hAQP1 if approved.","Underwriting agreement with BofA Securities, Inc. and Goldman Sachs & Co. LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95076,"accession_number":"0001104659-26-044028","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["1.01","1.02","2.01","7.01","8.01","9.01"],"status":"ready","headline":"MeiraGTx acquires bota-vec gene therapy from Janssen for XLRP treatment","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["MeiraGTx paid $25M upfront to Janssen for bota-vec, with a potential $50M milestone upon US approval and $250M sales threshold.","Phase 3 LUMEOS trial showed 40% of treated patients improved in ≥2 endpoints vs 0% in control.","MeiraGTx intends to file BLA and MAA in US, EU, and Japan for bota-vec, targeting potential launch in 2027.","JJDC, Johnson & Johnson investment arm, owns >5% of MeiraGTx shares and agreed to 12-month lock-up.","Estimated >20,000 XLRP patients in US and EU, with potential peak market of $1.7B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95075,"accession_number":"0001104659-26-044025","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MeiraGTx reports positive 3-year Phase 1 data for AAV-hAQP1 in radiation-induced xerostomia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["62% of patients had ≥10-point XQ improvement at 36 months; average 17-point improvement maintained from 12 months.","Unstimulated saliva flow normalized to average 0.36 mL/min at 12 months, maintained at 0.34 mL/min at 36 months.","No dose-limiting toxicity or treatment-related serious adverse events; well tolerated at all doses.","Company estimates peak global revenue potential of $3.7B, U.S. peak of $2.0B, targeting ~165,000 U.S. patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107888,"accession_number":"0001104659-26-034904","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"MeiraGTx: FDA Breakthrough for xerostomia, FY2025 net loss $114.2M, $200M Hologen JV","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia; RMAT also granted.","Strategic JV with Hologen: $200M upfront, $230M additional funding for AAV-GAD, MeiraGTx holds 30% ownership.","Collaboration with Lilly: $75M upfront, >$400M milestones for AAV-AIPL1 and other ocular assets.","FY2025 net loss $114.2M ($1.42/share) vs $147.8M ($2.12/share) in FY2024; cash $68.2M.","Debt amendment: maturity extended to May 2027, $25M redemption by June 30, 2026, warrant price reduced to $8.00."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107887,"accession_number":"0001104659-26-000068","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MeiraGTx repurchases 2.3M shares from Perceptive Master Fund for $18.2M at $7.91 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bought 2,300,000 ordinary shares from Perceptive Life Sciences Master Fund at VWAP of $7.91, aggregate $18.2M.","Perceptive Master Fund and affiliates hold >10% of outstanding shares and a $75M note with the company.","Selling shareholder subject to 12-month lock-up on remaining Perceptive shares, with limited exceptions.","Perceptive Credit Holdings III consented to the repurchase under the Notes Purchase Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124302,"accession_number":"0001104659-25-110883","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx Q3 net loss $50.5M; enters ophthalmology collaboration with Lilly for $75M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration with Lilly: upfront $75M, eligible for >$400M milestones and tiered royalties on ocular programs.","Cash $14.8M at Sept 30; with Lilly $75M and Hologen $150M expected, runway into H2 2027 covers $75M debt due Aug 2026.","Net loss $50.5M ($0.62/share) vs $39.3M ($0.55) YoY; service revenue fell to $0.4M from $10.9M as J&J PPQ substantially completed.","AAV-hAQP1 Phase 2 enrollment target end of 2025; positive data could support BLA filing early 2027.","AAV-GAD Phase 3 for Parkinson's expected to initiate in coming months; RMAT designation granted."],"consensus_eps_estimate":-0.4998,"consensus_eps_actual":-1.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":6027000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124301,"accession_number":"0001104659-25-108804","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"MeiraGTx licenses AAV-AIPL1 and gene therapy tools to Lilly for $75M upfront, up to $400M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment of $75M; eligible for over $400M in total milestones, including up to $135M near-term.","Lilly gets exclusive worldwide rights to AAV-AIPL1 for LCA4, which restored vision in 11 blind children.","Also licenses proprietary intravitreal capsids, promoters (AI-generated), and riboswitch gene-editing rights.","MeiraGTx eligible for tiered royalties; retains ownership of certain technology improvements; Lilly funds all R&D and commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140973,"accession_number":"0001558370-25-011478","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx Q2 net loss narrows to $38.8M; FDA alignment on RIX pivotal study, RMAT for Parkinson's","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $38.8M ($0.48/sh) vs $48.6M ($0.76/sh) in Q2 2024; cash $32.2M at June 30, 2025.","FDA aligns on AAV-hAQP1 Phase 2 AQUAx2 as potentially pivotal for BLA in radiation-induced xerostomia; enrollment target Q4 2025, data late 2026.","FDA grants RMAT designation for AAV-GAD in Parkinson's; clean GCP inspection; Phase 3 study planned in 2025.","Received $23M of $200M from Hologen collaboration; forming JV Hologen Neuro AI with up to $230M funding for AAV-GAD development.","Preparing MAA in UK and BLA in US for AAV-AIPL1 in LCA4; Lancet publication shows all 11 treated children now able to see."],"consensus_eps_estimate":-0.4769,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":5617000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158743,"accession_number":"0001558370-25-008870","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"MeiraGTx receives UK FDI clearances for Hologen deal; closing expected July 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["UK foreign direct investment clearances obtained for proposed transactions with Hologen Limited.","Transactions originally entered into on March 9, 2025.","Closing now expected in July 2025.","No financial terms disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158742,"accession_number":"0001558370-25-008676","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MeiraGTx annual meeting elects director, ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Director Thomas E. Shenk elected with 40.3M votes for, 9.1M withheld, 9.9M broker non-votes.","Ernst & Young LLP ratified as auditor for FY2025 (45.4M for, 13.9M against, 34K abstain).","Annual meeting held June 12, 2025; 74.2% of shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158741,"accession_number":"0001558370-25-007497","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx Q1 net loss $40.0M; announces $200M Hologen AI collaboration, RMAT for AAV-GAD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $40.0M ($0.51/share) vs $20.4M ($0.32) YoY; revenue $1.9M; cash $66.5M.","Hologen AI collaboration: $200M upfront to MeiraGTx; joint venture with $230M committed capital.","FDA granted RMAT designation for AAV-GAD Parkinson's; Phase 3 study planned H2 2025.","AAV-AIPL1 data in Lancet: 11/11 children with LCA4 responded; expedited approval discussions underway.","Bota-vec Phase 3 XLRP trial primary endpoint not met; secondary endpoints showed benefit across vision domains."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":1926000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158740,"accession_number":"0001558370-25-007074","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA grants RMAT designation to MeiraGTx's AAV-GAD for Parkinson's disease","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["RMAT designation based on data from three clinical studies (Phase 1 n=12, Phase 2 n=45, dose-ranging n=14).","AAV-GAD showed significant benefit on UPDRS Part 3 motor endpoint in double-blind sham-controlled trials.","Hologen AI analysis indicated disease-modifying brain circuitry changes, first in sham-controlled Parkinson's study.","RMAT includes Fast Track and Breakthrough Therapy benefits, rolling review, and potential Priority Review for BLA.","MeiraGTx plans to work closely with FDA to advance this one-time gene therapy for Parkinson's disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158739,"accession_number":"0001558370-25-004490","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"MeiraGTx enters 7yr7mo lease for 14,235 sq ft NYC lab; terminates prior sublease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New lease with ARE-East River Science Park for lab/office space at $111/sq ft/yr, 3% annual escalations.","Landlord contributes $50/sq ft ($712K) toward tenant improvements; rent abated first 4 months plus a period in year 2.","Initial term ~7yr7mo with a 5-year extension option; expected commencement between July and August 2025.","Existing sublease with ImClone Systems terminated early, from Oct 2026 to ~Aug 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177139,"accession_number":"0001558370-25-002859","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"MeiraGTx enters collaboration with Hologen AI: $200M upfront, $230M JV funding for AAV-GAD","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Received $200M upfront cash from Hologen; forming JV Hologen Neuro AI Ltd.","Hologen commits up to $230M additional capital to JV to fund AAV-GAD Parkinson's development.","MeiraGTx retains 30% ownership in JV, leads clinical development and manufacturing.","Hologen takes minority stake in MeiraGTx's manufacturing subsidiary; AI optimization.","Closing expected Q2 2025, subject to UK FDI regulatory approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193920,"accession_number":"0001558370-24-016089","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MeiraGTx granted FDA RMAT designation for AAV2-hAQP1 in Grade 2/3 radiation-induced xerostomia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA's RMAT designation includes Fast Track, Breakthrough Therapy benefits and potential Priority Review and accelerated approval.","Phase 1 AQUAx trial showed significant patient-reported outcomes and saliva production improvements with no serious adverse events.","Phase 2 AQUAx2 double-blind, placebo-controlled trial is enrolling; FDA agreed Phase 2 may serve as pivotal trial for BLA filing.","AAV2-hAQP1 previously received FDA Orphan Drug Designation for this indication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193919,"accession_number":"0001558370-24-015441","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx secures MHRA pathway for AAV-AIPL1 approval without further studies; Q3 net loss $39.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["AAV-AIPL1 MAA under exceptional circumstances agreed with MHRA; no further clinical studies required for UK approval.","11 blind children treated with AAV-AIPL1 all gained vision within 4+ weeks; FDA discussions initiated for similar US pathway.","AAV-GAD bridging study met safety endpoint; 18-point improvement in UPDRS Part 3 'off' score (p=0.03) at Week 26.","Three FDA Rare Pediatric Disease Designations awarded for AIPL1, BBS10, and RDH12 programs.","Cash $122.9M + $3.3M receivables; net loss $39.3M ($0.55 per share) vs $44.3M ($0.74) YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":11889000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193918,"accession_number":"0001558370-24-013273","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MeiraGTx reports positive Phase 2 data for AAV-GAD in Parkinson's; 18-point UPDRS improvement in high-dose group","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AAV-GAD met primary safety endpoint; no SAEs related to treatment in 14-patient bridging study.","High-dose group showed 18-point average improvement in UPDRS Part 3 off-medication (p=0.03); sham and low-dose showed no significant change.","PDQ-39 quality-of-life score improved by 8 points (p=0.02) in high-dose and 6 points (p=0.04) in low-dose groups.","100% of high-dose participants reported PDQ-39 improvement vs 60% low-dose and 25% sham.","Company plans to advance AAV-GAD into Phase 3 trial globally; total of 58 patients treated across program with no related SAEs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210245,"accession_number":"0001104659-24-089011","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MeiraGTx closes public offering of 12.5M shares at $4.00, netting $48.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 12,500,000 ordinary shares at $4.00/share completed August 13, 2024; net proceeds ~$48.3M.","Proceeds intended for general corporate purposes, including working capital and capital expenditures.","Company expects existing cash plus net proceeds and near-term J&J milestones to fund operations into Q2 2026.","J&J Asset Purchase Agreement provides up to $285M in milestone payments upon first commercial sale of bota-vec for XLRP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210244,"accession_number":"0001558370-24-011797","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx reports Q2 net loss of $48.6M and $50M offering led by Sanofi","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $48.6M ($0.76/share) vs $29.6M ($0.53) in Q2 2023; service revenue $0.3M, no license revenue.","Offering of 12.5M shares at $4.00 each for $50M gross proceeds; led by Sanofi ($30M) with Perceptive Advisors.","Cash and equivalents $100.0M as of June 30, 2024; believes funded into Q2 2026 with $285M potential J&J milestones.","Phase 2 AQUAx2 for xerostomia enrolling; FDA aligned on pivotal trial design. AAV-GAD for Parkinson's results expected Q4 2024.","UK ILAP designation for AAV-AIPL1 in LCA4; all 11 treated blind children gained visual acuity. Riboswitch platform data later 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228537,"accession_number":"0001558370-24-009041","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MeiraGTx 2024 AGM results: directors elected, say-on-pay approved, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three Class III directors elected: Forbes (99.8% cast, 49.6M for), Harris (99.5%), Mendoza (99.7%).","Advisory say-on-pay approved with 49.3M for (99.2% of votes cast excluding broker non-votes).","Shareholders selected 3-year frequency for future advisory say-on-pay votes (27.2M for 3 years).","Ratification of Ernst & Young as FY2024 auditor passed with 55.3M for (99.8% of votes cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228536,"accession_number":"0001558370-24-007476","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx Q1 net loss narrows to $20.4M; receives $50M milestone from Janssen","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to shareholders $20.4M ($0.32 per share) vs $30.4M ($0.62) in Q1 2023.","Cash and cash equivalents $119.2M at March 31; $138.9M after April collections; runway into Q1 2026.","Received $50M milestone from Janssen for Phase 3 LUMEOS extension study initiation for bota-vec in XLRP.","Phase 1 AQUAx data showed 112.8% increase in unstimulated saliva flow at 12 months; pivotal Phase 2 enrolling.","Completed dosing in Phase 1 bridging study for AAV-GAD Parkinson's gene therapy; Phase 3 design discussions in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":697000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228535,"accession_number":"0001558370-24-005201","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K/A","filed_at":"2024-04-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MeiraGTx amends prior 8-K to disclose Dr. Debra Yu's committee appointments","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Debra Yu, M.D., joined the Board on April 25, 2022; this amendment adds committee assignments.","Effective April 15, 2024, Dr. Yu appointed to both Compensation Committee and Science & Technology Committee.","Amendment relates solely to disclosure of committee appointments; no other changes to prior filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247198,"accession_number":"0001558370-24-003175","cik":1735438,"company_name":"MeiraGTx Holdings plc","ticker":"MGTX","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MeiraGTx reports FY2023 net loss of $84M, down 35% YoY; Janssen deal yields $50M milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $84.0M ($1.49/share) vs $129.6M ($2.87) in 2022; license revenue $14.0M.","Janssen asset purchase for bota-vec (XLRP) up to $415M; $65M upfront + $50M milestone in Feb 2024.","Sanofi invested $30M at $7.50/share; ROFN for riboswitch in CNS, I&I, metabolic disease.","FDA aligns Phase 2 AQUAx2 for xerostomia as pivotal; AAV-AIPL1 shows meaningful responses in 8 LCA4 children.","Cash $129.6M at Dec 31, 2023; expects funding into Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":910351538.0657228,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}